748 related articles for article (PubMed ID: 22343605)
1. Prostate-specific antigen screening for prostate cancer in older men in the United States of America.
Black A; Berg CD
Gerontology; 2012; 58(4):331-6. PubMed ID: 22343605
[TBL] [Abstract][Full Text] [Related]
2. Screening for prostate cancer: the current evidence and guidelines controversy.
Gomella LG; Liu XS; Trabulsi EJ; Kelly WK; Myers R; Showalter T; Dicker A; Wender R
Can J Urol; 2011 Oct; 18(5):5875-83. PubMed ID: 22018148
[TBL] [Abstract][Full Text] [Related]
3. Prostate cancer screening in men 75 years old or older: an assessment of self-reported health status and life expectancy.
Hoffman KE; Nguyen PL; Ng AK; D'Amico AV
J Urol; 2010 May; 183(5):1798-802. PubMed ID: 20299039
[TBL] [Abstract][Full Text] [Related]
4. Prostate Cancer Screening and the Associated Controversy.
Tabayoyong W; Abouassaly R
Surg Clin North Am; 2015 Oct; 95(5):1023-39. PubMed ID: 26315521
[TBL] [Abstract][Full Text] [Related]
5. [Clinical value of prostate specific antigen screening in early detection of prostate cancer].
Hua LX; Qiao D; Song NH; Feng NH; Yang J; Zhang JX; Chen JG; Zhang W; Sui YG; Wu HF
Zhonghua Zhong Liu Za Zhi; 2009 Sep; 31(9):705-9. PubMed ID: 20021870
[TBL] [Abstract][Full Text] [Related]
6. Prostate specific antigen best practice statement: 2009 update.
Greene KL; Albertsen PC; Babaian RJ; Carter HB; Gann PH; Han M; Kuban DA; Sartor AO; Stanford JL; Zietman A; Carroll P
J Urol; 2009 Nov; 182(5):2232-41. PubMed ID: 19781717
[TBL] [Abstract][Full Text] [Related]
7. National trends in prostate cancer screening among older American men with limited 9-year life expectancies: evidence of an increased need for shared decision making.
Drazer MW; Prasad SM; Huo D; Schonberg MA; Dale W; Szmulewitz RZ; Eggener SE
Cancer; 2014 May; 120(10):1491-8. PubMed ID: 24523016
[TBL] [Abstract][Full Text] [Related]
8. Prostate-specific antigen-based screening for prostate cancer: evidence, controversies and future perspectives.
Ito K
Int J Urol; 2009 May; 16(5):458-64. PubMed ID: 19341365
[TBL] [Abstract][Full Text] [Related]
9. Screening for prostate cancer: prostate-specific antigen testing is not effective.
Hitzeman N; Molina M
Am Fam Physician; 2011 Apr; 83(7):802-4. PubMed ID: 21524045
[No Abstract] [Full Text] [Related]
10. Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement.
; Grossman DC; Curry SJ; Owens DK; Bibbins-Domingo K; Caughey AB; Davidson KW; Doubeni CA; Ebell M; Epling JW; Kemper AR; Krist AH; Kubik M; Landefeld CS; Mangione CM; Silverstein M; Simon MA; Siu AL; Tseng CW
JAMA; 2018 May; 319(18):1901-1913. PubMed ID: 29801017
[TBL] [Abstract][Full Text] [Related]
11. Baseline prostate-specific antigen testing at a young age.
Loeb S; Carter HB; Catalona WJ; Moul JW; Schroder FH
Eur Urol; 2012 Jan; 61(1):1-7. PubMed ID: 21862205
[TBL] [Abstract][Full Text] [Related]
12. Prostate-specific antigen levels in the United States: implications of various definitions for abnormal.
Welch HG; Schwartz LM; Woloshin S
J Natl Cancer Inst; 2005 Aug; 97(15):1132-7. PubMed ID: 16077071
[TBL] [Abstract][Full Text] [Related]
13. A model of prostate-specific antigen screening outcomes for low- to high-risk men: information to support informed choices.
Howard K; Barratt A; Mann GJ; Patel MI
Arch Intern Med; 2009 Sep; 169(17):1603-10. PubMed ID: 19786680
[TBL] [Abstract][Full Text] [Related]
14. Re: Prostate cancer screening in men 75 years old or older: an assessment of self-reported health status and life expectancy. K. E. Hoffman, P. L. Nguyen, A. K. Ng and A. V. D'Amico. J Urol 2010; 183: 1798-1802.
Neulander EZ
J Urol; 2011 May; 185(5):1982; author reply 1983. PubMed ID: 21421243
[No Abstract] [Full Text] [Related]
15. American Cancer Society guideline for the early detection of prostate cancer: update 2010.
Wolf AM; Wender RC; Etzioni RB; Thompson IM; D'Amico AV; Volk RJ; Brooks DD; Dash C; Guessous I; Andrews K; DeSantis C; Smith RA;
CA Cancer J Clin; 2010; 60(2):70-98. PubMed ID: 20200110
[TBL] [Abstract][Full Text] [Related]
16. Use and assessment of PSA in prostate cancer.
Gjertson CK; Albertsen PC
Med Clin North Am; 2011 Jan; 95(1):191-200. PubMed ID: 21095422
[TBL] [Abstract][Full Text] [Related]
17. Prostate specific antigen best practice statement: 2009 update.
Greene KL; Albertsen PC; Babaian RJ; Carter HB; Gann PH; Han M; Kuban DA; Sartor AO; Stanford JL; Zietman A; Carroll P;
J Urol; 2013 Jan; 189(1 Suppl):S2-S11. PubMed ID: 23234625
[TBL] [Abstract][Full Text] [Related]
18. Why are a high overdiagnosis probability and a long lead time for prostate cancer screening so important?
Barry MJ; Mulley AJ
J Natl Cancer Inst; 2009 Mar; 101(6):362-3. PubMed ID: 19276451
[No Abstract] [Full Text] [Related]
19. Prostate cancer screening.
Sikaris K
Pathology; 2012 Feb; 44(2):99-109. PubMed ID: 22198258
[TBL] [Abstract][Full Text] [Related]
20. Screening for prostate cancer: a guidance statement from the Clinical Guidelines Committee of the American College of Physicians.
Qaseem A; Barry MJ; Denberg TD; Owens DK; Shekelle P;
Ann Intern Med; 2013 May; 158(10):761-769. PubMed ID: 23567643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]